{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:54Z","timestamp":1793146674682,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019203","name":"ImmunoGen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ygyno.2024.01.045","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T18:45:13Z","timestamp":1709664313000},"page":"186-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)\u2013targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer"],"prefix":"10.1016","volume":"185","author":[{"given":"Debra L.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina M.","family":"Mantia-Smaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar M.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Method","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.01.045_bb0005","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fonc.2013.00251","article-title":"Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment","volume":"3","author":"Chien","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0015","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0020","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0025","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the gynecologic cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/fon-2019-0042","article-title":"Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer","volume":"16","author":"Haunschild","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0040","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0050","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-014-9539-8","article-title":"Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications","volume":"34","author":"Vergote","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0060","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0065","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-alpha (FRalpha)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRalpha-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0070","series-title":"Elahere [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.ygyno.2024.01.045_bb0075","first-page":"OF1","article-title":"FDA approval summary: mirvetuximab soravtansine-Gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","author":"Dilawari","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0080","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0085","series-title":"Presented at: 2023 American Society of Clinical Oncology Annual Meeting June 2\u20136, Chicago, IL","first-page":"LBA5507","author":"Moore","year":"2023"},{"key":"10.1016\/j.ygyno.2024.01.045_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0095","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0100","article-title":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","volume":"47","author":"Hendershot","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","article-title":"Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer","volume":"151","author":"Moore","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0115","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1200\/JCO.2020.38.15_suppl.6004","article-title":"Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer","volume":"38","author":"Gilbert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.01.045_bb0130","series-title":"VENTANA FOLR1 (FOLR1\u20132.1) RxDx Assay [Interpretation Guide for EOC]","year":"2022"},{"key":"10.1016\/j.ygyno.2024.01.045_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx450","article-title":"Front-line therapy of advanced epithelial ovarian cancer: standard treatment","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0145","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0155","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0160","doi-asserted-by":"crossref","first-page":"415","DOI":"10.20517\/cdr.2022.01","article-title":"Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments?\u202f: A clinical perspective","volume":"5","author":"Rose","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncologist."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0170","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1359-6349(15)70005-4","article-title":"Limitations to the use of carboplatin-based therapy in advanced ovarian cancer","volume":"12","author":"Fotopoulou","year":"2014","journal-title":"EJC Suppl."},{"key":"10.1016\/j.ygyno.2024.01.045_bb0185","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:35:14Z","timestamp":1732610114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":36,"alternative-id":["S0090825824000714"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.045","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)\u2013targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}